Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;4(7):1222-9.
doi: 10.2215/CJN.01260209. Epub 2009 Jun 18.

Encapsulating peritoneal sclerosis in the new millennium: a national cohort study

Michaela C Brown  1 , Keith Simpson, Jan J Kerssens, Robert A Mactier; Scottish Renal Registry
Affiliations

Encapsulating peritoneal sclerosis in the new millennium: a national cohort study

Michaela C Brown et al. Clin J Am Soc Nephrol. 2009 Jul.

Abstract

Background and objectives: The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD).

Design, setting, participants, & measurements: The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria.

Results: Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at <1, 1 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed <2 yr after PD stopped. The cases had a median of 3.3 episodes of peritonitis (range 0 to 20, IQR 1 to 4.5). Thirty (65%) had used 3.86% dextrose dialysate and 45 (98%) had used Extraneal. The mortality was 42% at 1 yr postdiagnosis with a median survival of 149 d (IQR 61 to 408 d).

Conclusions: The incidence reported in this study may be used to inform patients of the minimum risk of developing EPS on PD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative risk function of developing EPS according to days since first PD exposure between January 1, 2000, and December 31, 2007.
Figure 2.
Figure 2.
(A) PD Duration: Non-EPS cohort first exposed to PD after January 1, 2000 (n = 1219). (B) PD Duration: EPS cases first exposed to PD after January 1, 2000 (n = 19).
Figure 3.
Figure 3.
Kaplan-Meier survival plots of patients from start of PD for EPS cases (n = 19) and unaffected cohort (n = 1219).
See this image and copyright information in PMC

References

    1. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, Geis WP, Hano JE: Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Int Med 140: 1201–1203, 1980 - PubMed
    1. Kawanishi H: Long-Term Peritoneal Dialysis Study Group: Encapsulating peritoneal sclerosis in Japan: Prospective multicentre controlled study. Perit Dial Int 21(S3): S67–S71, 2001 - PubMed
    1. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nakamoto M, Ohira S, Shoji T: Encapsulating peritoneal sclerosis in Japan: A prospective. Controlled, Multicentre Study Am J Kidney Dis 44(4): 729–737, 2004 - PubMed
    1. Rigby RJ, Hawley CM: Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 13: 154–159, 1998 - PubMed
    1. Lee HY, Kim BS, Choi HY, Park HC, Kang SW, Choi KH, Ha SK, Han DS: Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrol. (Carlton) 8: S33–S39, 2003 - PubMed

MeSH terms